sovleplenib
sovleplenib: 5 clinical trials tracked.
sovleplenib evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about sovleplenib, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (5)
An Open-Label, Randomized, Three-Period, Six-Sequence Phase I Study to Evaluate the Effect of Food on the Pharmacokinetics of HMPL-523 Acetate Tablets in Healthy Participants
Primary endpoint: AUC0-t
A Multicenter, Phase 1b Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523, a Syk Inhibitor, in Adult Subjects With Immune Thrombocytopenia
Primary endpoint: Safety and tolerability of HMPL-523 in adult subjects with primary ITP
A Randomized, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HMPL-523 in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Primary endpoint: Phase II: Overall Hb response rate
A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HMPL-523 in Treatment of Primary Immune Thrombocytopenia (ITP) in Adults (ESLIM-01 Study)
Primary endpoint: the durable response rate in the primary study
A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Patients With Relapsed or Refractory Lymphoma
Primary endpoint: Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs)